Kizoo Technology Capital

Kizoo Technology Capital is a venture capital firm based in Karlsruhe, Germany, founded in 1999 by Michael Greve, Frank Schueler, and Matthias Hornberger. Part of the Mira Holding group alongside sister organization Forever Healthy Foundation, the firm manages a fund of approximately $349 million and has made 54 investments over its history. Kizoo now focuses exclusively on rejuvenation and longevity biotech, backing never-done-before technologies aimed at extending healthy human lifespans by addressing the root causes of aging. Patrick Burgermeister serves as Partner. The firm leads rounds and typically invests at the Seed and Series A stages, with check sizes ranging from $1 million to $10 million. Current active portfolio companies tackle age-related cellular damage from multiple angles: Cellvie (a Harvard spin-off developing mitochondria transfer therapy), Reservoir Neuroscience (brain vascular rejuvenation, $4 million financing in 2024), Cyclarity (arterial plaque removal), Elastrin (tissue decalcification), Revel Pharmaceuticals (collagen crosslink breakers, Yale-originated), and MoglingBio (stem cell rejuvenation). Many of these companies were seeded directly from university research at SENS lab, Yale, Harvard, Clemson, and UC Berkeley. Kizoo's legacy internet and SaaS portfolio includes early seed investments in several German unicorns — Staffbase, Mambu, and Babbel — though the firm no longer makes new investments in those sectors. Kizoo's approach is thesis-driven and deeply hands-on: the team partners with academic founders to help create companies from scratch, often before commercial infrastructure exists. The firm invests across Europe and the United States, reflecting the global nature of longevity science. Three portfolio companies have been acquired, most recently Shyftplan, which was acquired by Maguar in June 2024.